Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 4Stage I Prostate Adenocarcinoma AJCC v7 1Salivary Gland Neoplasms 1PSA Level Greater Than Two 1Granulosa cell tumor of the ovary 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3trastuzumab deruxtecan 2Cisplatin 2Biopsy 2pembrolizumab 1luprolide acetate gel depot 1entrectinib 1dehydroftorafur 1darolutamide 1ceralasertib 1apalutamide 1amivantamab 1Surveys and Questionnaires 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Platinum 1Pemetrexed 1Leuprolide 1Immunoglobulin G 1Gonadotropin-Releasing Hormone 1Glutamate Carboxypeptidase II 1Fluorouracil 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × luprolide acetate gel depot × 30 days × Clear all
NCT05669664 2026-05-13

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
21 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡